- Home
- BNTX vs CBOE Comparison
BNTX vs CBOE Comparison
Compare BNTX & CBOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNTX | CBOE |
|---|---|---|
| Founded | 2008 | 1973 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 26.8B |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BNTX | CBOE |
|---|---|---|
| Price | $96.50 | $247.76 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 11 |
| Target Price | $137.40 | ★ $246.64 |
| AVG Volume (30 Days) | ★ 1.2M | 586.0K |
| Earning Date | 11-03-2025 | 02-06-2026 |
| Dividend Yield | N/A | ★ 1.16% |
| EPS Growth | N/A | ★ 26.68 |
| EPS | N/A | ★ 9.30 |
| Revenue | $3,698,814,972.00 | ★ $4,617,800,000.00 |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | N/A | $5.64 |
| P/E Ratio | ★ N/A | $26.68 |
| Revenue Growth | 3.70 | ★ 16.74 |
| 52 Week Low | $81.20 | $187.30 |
| 52 Week High | $129.27 | $262.98 |
Technical Indicators
Market Signals| Indicator | BNTX | CBOE |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 42.18 |
| Support Level | $94.00 | $245.34 |
| Resistance Level | $95.71 | $258.07 |
| Average True Range (ATR) | 1.72 | 4.29 |
| MACD | 0.62 | -0.29 |
| Stochastic Oscillator | 81.33 | 24.92 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.